In comparison with studies testing CD28-based anti-BCMA CAR T cells, 41BB-based CAR T cells displayed improved persistence and a lower rate of toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [27]. This evidence concerns the gene CD28 and congenital rubella syndrome.